Çalışmamızda 20 KOAH olguya her ilaç farklı günlerde olmak üzere inhalasyon yoluyla pirenzepine'in üç ayrı dozu (3:12, 50, 200mcg) salbutamol ve ipratropium bromide verildi. İlaçlar uygulandıktan sonra 15, 30, 60, 120 ve 180.'dklarda solunum fonksiyon testleri yapıldı. FEVİ, FEF25-75 ve FEF50 parametrelerinde ilaçların bronkodilatör etkinlikleri karşılaştırıldı. Pirenzepine'in üç ayrı dozunda da hem büyük hava yollarında (FEVİ) hem de küçük hava yollarında (FEF25-75,FEF50) anlamlı bronkodilatör etkinliği saptanmadı. Bununla birlikte pirenzepine'in üç ayrı dozunun birbirlerine anlamlı üstünlükleri tespit edilemedi. Olgularda salbutamol ile ipratropium bromide'in etkinlikleri arasında anlamlı fark saptanamadı. Ancak gerek salbutamol gerekse i...
WOS: 000386264100003PubMed ID: 27481077Introduction: The treatment of COPD (Chronic Obstructive Pulm...
AbstractThe bronchodilatory effect of four doses of salbutamol powder (1·6 mg) from a multi-dose dry...
Keisaku Fujimoto1, Yoshiaki Kitaguchi2, Shintaro Kanda2, Kazuhisa Urushihata2, Masayuki Hanaoka2, Ke...
Çalışmamızda 20 KOAH olguya her ilaç farklı günlerde olmak üzere inhalasyon yoluyla pirenzepine'in ü...
Ipratropium bromide (IB) is a non-selective muscarinic antagonist, whose bronchodilator efficacy has...
Contains fulltext : 59011.pdf (publisher's version ) (Open Access)Inhalation thera...
Background. The morbidity from obstructive airways disease (asthma and chronic obstructive pulmonary...
AbstractTo compare the effects of salmeterol, an adrenergic drug, and ipratropium bromide, an antich...
SummaryBackground: Patients with chronic obstructive pulmonary disease (COPD) often report greater r...
Item does not contain fulltextOBJECTIVE. This open randomized study examined differences between the...
SummaryWe compared the efficacy and safety of ipratropium bromide/albuterol delivered via Respimat® ...
Amaç: Son çalışmalarda, kronik obstrüktif akciğer hastalığı (KOAH) olgularında k ombine preparat (uz...
Background: Chronic Obstructive Pulmonary Disease (COPD) is a clinical syndrome associated with grad...
Contains fulltext : 48548.pdf (publisher's version ) (Closed access)BACKGROUND: In...
Two studies are presented, with the aim of establishing the dose potency ratio for salbutamol given ...
WOS: 000386264100003PubMed ID: 27481077Introduction: The treatment of COPD (Chronic Obstructive Pulm...
AbstractThe bronchodilatory effect of four doses of salbutamol powder (1·6 mg) from a multi-dose dry...
Keisaku Fujimoto1, Yoshiaki Kitaguchi2, Shintaro Kanda2, Kazuhisa Urushihata2, Masayuki Hanaoka2, Ke...
Çalışmamızda 20 KOAH olguya her ilaç farklı günlerde olmak üzere inhalasyon yoluyla pirenzepine'in ü...
Ipratropium bromide (IB) is a non-selective muscarinic antagonist, whose bronchodilator efficacy has...
Contains fulltext : 59011.pdf (publisher's version ) (Open Access)Inhalation thera...
Background. The morbidity from obstructive airways disease (asthma and chronic obstructive pulmonary...
AbstractTo compare the effects of salmeterol, an adrenergic drug, and ipratropium bromide, an antich...
SummaryBackground: Patients with chronic obstructive pulmonary disease (COPD) often report greater r...
Item does not contain fulltextOBJECTIVE. This open randomized study examined differences between the...
SummaryWe compared the efficacy and safety of ipratropium bromide/albuterol delivered via Respimat® ...
Amaç: Son çalışmalarda, kronik obstrüktif akciğer hastalığı (KOAH) olgularında k ombine preparat (uz...
Background: Chronic Obstructive Pulmonary Disease (COPD) is a clinical syndrome associated with grad...
Contains fulltext : 48548.pdf (publisher's version ) (Closed access)BACKGROUND: In...
Two studies are presented, with the aim of establishing the dose potency ratio for salbutamol given ...
WOS: 000386264100003PubMed ID: 27481077Introduction: The treatment of COPD (Chronic Obstructive Pulm...
AbstractThe bronchodilatory effect of four doses of salbutamol powder (1·6 mg) from a multi-dose dry...
Keisaku Fujimoto1, Yoshiaki Kitaguchi2, Shintaro Kanda2, Kazuhisa Urushihata2, Masayuki Hanaoka2, Ke...